Methods, precision, and analytical sensitivity of a novel low‐plasma‐volume assay of fibrinolytic capacity utilizing the euglobulin fraction
International Journal of Laboratory Hematology · 2024
DOI: 10.1111/ijlh.14340 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2024. Verfasst von Steven Bruzek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA. Hauptthemen laut MEDLINE: Fibrinolysis, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Introduction
Fibrinolysis is a critical aspect of the hemostatic system, with assessment of fibrinolytic potential being critical to predict bleeding and clotting risk. We describe the method for a novel low‐plasma‐volume assay of fibrinolytic capacity utilizing the euglobulin fraction (the “modified mini‐euglobulin clot lysis assay [ECLA]”), its analytic sensitivity to alterations in key fibrinolytic substrates/regulators, and its initial applications in acute and convalescent disease cohorts.
Methods
The modified mini‐ECLA requires 50 μL of plasma, a maximal read time of 3 h (with most results available within 60 min), and is entirely performed in a 96‐well microplate. Assay measurements were obtained in a variety of commercial control and deficient plasmas representing clinically relevant hypo‐ and hyperfibrinolytic states, and in three distinct adolescent cohorts with acute or convalescent illness: critically ill, following endotracheal intubation; acute COVID‐19‐related illness; and ambulatory, 3 months following a venous thromboembolic event.
Results
In 100% and 75% deficient plasmas, hypofibrinolysis for plasminogen‐deficient, fibrinolysis for alpha‐2‐antiplasmin‐deficient, and hyperfibrinolysis for plasminogen activator inhibitor‐1‐deficient plasmas were observed.
Conclusion
The modified mini‐ECLA Clot Lysis Time Ratio (“CLTR”) demonstrated moderate‐strength correlations with the Clot Formation and Lysis (CloFAL) assay, is analytically sensitive to altered fibrinolytic states in vitro, and correlates with clinical outcomes in preliminarily‐studied patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
- Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Steven Bruzek
Zitieren
APA
Bruzek, S., Betensky, M., Sochet, A. A., Goldenberg, N. A., & Ignjatovic, V. (2024). Methods, precision, and analytical sensitivity of a novel low‐plasma‐volume assay of fibrinolytic capacity utilizing the euglobulin fraction. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14340
Vancouver
Bruzek S, Betensky M, Sochet AA, Goldenberg NA, Ignjatovic V. Methods, precision, and analytical sensitivity of a novel low‐plasma‐volume assay of fibrinolytic capacity utilizing the euglobulin fraction. International Journal of Laboratory Hematology. 2024. doi:10.1111/ijlh.14340
BibTeX
@article{Bruzek2024,
author = {Bruzek, Steven and Betensky, Marisol and Sochet, Anthony A and Goldenberg, Neil A and Ignjatovic, Vera},
title = {Methods, precision, and analytical sensitivity of a novel low‐plasma‐volume assay of fibrinolytic capacity utilizing the euglobulin fraction},
journal = {International Journal of Laboratory Hematology},
year = {2024},
doi = {10.1111/ijlh.14340}
}
EUVIMED